title: [A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis].
abstract: BACKGROUND
  The hyperphosphatemia, hypocalcemia and low calcitriol levels are pathogenic factors for secondary hyperparathyroidism in chronic renal failure. The phosphorus control is essential to prevent secondary hyperparathyroidism. There are not comparatives studies to test the efficacy of control of phosphorus binders in predialysis patients.
  
  
  OBJECTIVE
  To compare the efficacy of calcium carbonate vs calcium acetate as phosphate binder in predialysis patients.
  
  
  METHODS
  The present study includes 28 patients with chronic renal failure (mean clearance of creatinine 21 ml/min). Patients were separated into two groups: Group 1: (n = 14) received calcium carbonate 2,500 mg/day (1,000 mg of calcium); Group 2: (n = 14) receives calcium acetate 1,000 mg (254 mg of calcium). Calcium and phosphorus were determined every 4 months; i-PTH, alkaline phosphatase and clearance of creatinine were determined every six months.
  
  
  RESULTS
  Both groups were comparable regarding age, renal function, calcium, phosphorus, alkaline phosphatase and i-PTH on basal situation and the end of study were not different. The serum calcium increased, not significantly, in the calcium carbonate group (group 1) [from 9.2 to 9.8 mg/dl (p = 0.05)], however it was not modified in the calcium acetate group (group 2). The serum phosphorus decreased significantly (p < 0.05) in both groups, independently of the calcium levels. Alkaline phosphatase and i-PTH not was modified during the study period.
  
  
  CONCLUSIONS
  1) Both calcium carbonate and calcium acetate are similarly effective as phosphate binder. 2) The carbonate group required four fold greater doses of calcium that acetate group. 3) The calcium acetate has less hypercalcemic effect than calcium carbonate.
authors.affiliation: Servicio de Nefrología, Hospital General de Especialidades Ciudad de Jaén, Jaén.
authors.forename: J
authors.initials: J
authors.lastname: Borrego
authors.forename: P
authors.initials: P
authors.lastname: Pérez del Barrio
authors.forename: P
authors.initials: P
authors.lastname: Serrano
authors.forename: M J
authors.initials: MJ
authors.lastname: García Cortés
authors.forename: M C
authors.initials: MC
authors.lastname: Sánchez Perales
authors.forename: F J
authors.initials: FJ
authors.lastname: Borrego
authors.forename: A
authors.initials: A
authors.lastname: Liébana
authors.forename: J M
authors.initials: JM
authors.lastname: Gil Cunquero
authors.forename: V
authors.initials: V
authors.lastname: Pérez Bañasco
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000627:therapeutic use*; D017610:Calcium Compounds; D002614:Chelating Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010758:Phosphorus; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000209:etiology / Q000628:therapy*
chemical_list: D000085:Acetates; D017610:Calcium Compounds; D002614:Chelating Agents; D010758:Phosphorus; D002119:Calcium Carbonate; D002118:Calcium; C120662:calcium acetate